
Wen-Kai Weng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11729308/publications.pdf Version: 2024-02-01



WEN-KALWENC

#	Article	IF	CITATIONS
1	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	0.6	11
2	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , .	0.6	3
3	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	0.6	51
4	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	2.5	92
5	Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 2021, , 1-11.	0.6	0
6	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 405.e1-405.e6.	0.6	4
7	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation, 2021, 56, 2664-2671.	1.3	9
8	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	15.2	273
9	NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology, 2021, , .	0.6	0
10	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. Blood, 2021, 138, 3885-3885.	0.6	2
11	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. Blood, 2021, 138, 741-741.	0.6	4
12	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	0.6	0
13	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	0.6	0
14	Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. Practical Radiation Oncology, 2019, 9, 220-225.	1.1	4
15	Gain of CD26 expression on the malignant Tâ€cells in relapsed erythrodermic leukemic mycosis fungoides. Journal of Cutaneous Pathology, 2017, 44, 462-466.	0.7	2
16	Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation. Journal of the American Academy of Dermatology, 2017, 77, 706-712.	0.6	22
17	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation, 2015, 50, 1004-1006.	1.3	1
18	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology, 2015, 33, 3750-3758.	0.8	235

Wen-Kai Weng

#	Article	IF	CITATIONS
19	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 1878-1880.	0.6	4
20	Total Lymphoid Irradiation–Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20, 837-843.	2.0	18
21	Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 2014, 124, 2668-2682.	3.9	154
22	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS). Blood, 2014, 124, 2544-2544.	0.6	15
23	Use of High-Throughput Sequencing (HTS) of TCRß to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. Blood, 2014, 124, 2473-2473.	0.6	0
24	Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. Science Translational Medicine, 2013, 5, 214ra171.	5.8	84
25	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119, 6145-6154.	0.6	107
26	Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Journal of Clinical Investigation, 2012, 122, 1066-1075.	3.9	202
27	Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1679-1687.	2.0	125
28	Immunoglobulin G Fc Receptor Fcl ³ RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 279-284.	0.8	112
29	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 37-46.	0.6	39
30	Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leukemia and Lymphoma, 2009, 50, 1494-1500.	0.6	31
31	Genetic polymorphism of the inhibitory IgG Fc receptor Fc gamma RIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leukemia and Lymphoma, 2009, 50, 723-727.	0.6	32
32	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood, 2009, 114, 1099-1109.	0.6	150
33	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis Blood, 2009, 114, 3304-3304.	0.6	0
34	A Polymorphism in the Complement Component <i>C1qA</i> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 6697-6703.	3.2	149
35	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood, 2008, 112, 711-720.	0.6	97
36	Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood, 2007, 109, 951-953.	0.6	34

Wen-Kai Weng

#	Article	IF	CITATIONS
37	Rituximab Variants with Re-Engineered Fc with Higher Affinity to Activating Fcl ³ R Eliminate the Functional Difference between Fcl ³ R Genotypes Blood, 2005, 106, 347-347.	0.6	5
38	A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma Blood, 2005, 106, 778-778.	0.6	3
39	Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype Are Associated with Better Clinical Outcome Following Idiotype Vaccination in Follicular Lymphoma Patients Regardless of Their Response to Induction Chemotherapy Blood, 2005, 106, 777-777.	0.6	0
40	A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells Blood, 2005, 106, 2964-2964.	0.6	0
41	Use of Dendritic Cells and GM-CSF Adjuvant Are Associated with Anti-Idiotype Cellular Immune Response Following Idiotype Vaccination in Follicular Lymphoma Patients Blood, 2005, 106, 771-771.	0.6	1
42	Genetic Polymorphism of the Inhibitory IgG Fc Receptor FcÎ ³ RIIb Is Not Associated with Clinical Outcome of Rituximab Treated Follicular Lymphoma Patients Blood, 2005, 106, 2430-2430.	0.6	1
43	Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. Journal of Clinical Oncology, 2004, 22, 4717-4724.	0.8	190
44	A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma Blood, 2004, 104, 3279-3279.	0.6	5
45	Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation Blood, 2004, 104, 442-442.	0.6	3
46	Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients Blood, 2004, 104, 3250-3250.	0.6	0
47	Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2003, 21, 3940-3947.	0.8	1,245
48	Hepatitis C Virus (HCV) and Lymphomagenesis. Leukemia and Lymphoma, 2003, 44, 1113-1120.	0.6	92
49	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 2001, 98, 1352-1357.	0.6	207